	US 12,144,828 B2
	Human Kynureninase enzymes and uses thereof
George Georgiou, Austin, TX (US); Everett Stone, Austin, TX (US); John Blazeck, Austin, TX (US); and Christos Karamitros, Austin, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on Apr. 6, 2023, as Appl. No. 18/296,687.
Application 18/296,687 is a division of application No. 16/385,562, filed on Apr. 16, 2019, granted, now 11,648,272.
Claims priority of provisional application 62/658,261, filed on Apr. 16, 2018.
Prior Publication US 2023/0405049 A1, Dec. 21, 2023
Int. Cl. A61K 35/17 (2015.01); A61K 38/46 (2006.01); A61K 47/60 (2017.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01)

CPC A61K 35/17 (2013.01) [A61K 38/46 (2013.01); A61K 47/60 (2017.08); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12Y 307/01003 (2013.01)]

18 Claims

1. A method of treating a subject having a tumor, the method comprising administering to the subject a therapeutically effective amount of a modified kynureninase enzyme having an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1 and comprising at least one substitution selected from the group consisting of A99R, E103R, V104H, R107P, G112Y, I183P, and I331S.